首页 > 最新文献

International Journal of Cardiology Cardiovascular Risk and Prevention最新文献

英文 中文
Hypertension and lung cancer in China (2002–2019): A nationwide study of temporal trends, demographic disparities, and independent risk associations 中国高血压和肺癌(2002-2019):一项关于时间趋势、人口差异和独立风险关联的全国性研究
IF 2.1 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-12-01 Epub Date: 2025-09-12 DOI: 10.1016/j.ijcrp.2025.200515
Yang Yu , Chen Jiang , Yan gao , Dingqi Li , Chongcheng Xi , Quansheng Feng , Rui He

Background

Emerging evidence suggests a potential link between hypertension and cancer, yet the relationship between elevated blood pressure and lung cancer risk remains underexplored, particularly in large, population-based settings.

Objective

To investigate temporal trends in hypertension prevalence among lung cancer patients and to assess whether hypertension is independently associated with lung cancer risk in the Chinese adult population.

Methods

We analyzed data from 2,745,893 adults aged ≥18 years who participated in the China Chronic Disease and Risk Factor Surveillance (CCDRFS) program from 2002 to 2019. Trends in hypertension prevalence among lung cancer patients were assessed across demographic strata. Multivariable logistic regression models adjusted for age, sex, smoking, obesity, and region were used to estimate adjusted odds ratios (aORs) for lung cancer associated with hypertension.

Results

Among 168,427 lung cancer patients (6.1 % of total), 58.3 % had coexisting hypertension. Hypertension prevalence among lung cancer patients rose from 47.2 % in 2002 to 62.8 % in 2019, with sharper increases in rural (49.3 %–66.1 %) and western regions (50.4 %–66.9 %). After adjustment, hypertension was independently associated with lung cancer (aOR = 1.37; 95 % CI: 1.31–1.43), with stronger associations observed in females (aOR = 1.49), individuals aged ≥60 years (aOR = 1.54), non-smokers (aOR = 1.44), and obese participants (aOR = 1.46).

Conclusions

Hypertension is highly prevalent among lung cancer patients in China and appears to be independently associated with increased lung cancer risk. These findings suggest the need for integrated cardio-oncology surveillance and prevention strategies, particularly for high-risk subpopulations such as older adults, women, and non-smokers. Further prospective studies are warranted to explore the mechanisms underlying this association and to evaluate whether hypertension control may influence lung cancer burden.
背景:越来越多的证据表明高血压与癌症之间存在潜在联系,但血压升高与肺癌风险之间的关系仍未得到充分探讨,特别是在以人群为基础的大型环境中。目的探讨中国成年肺癌患者高血压患病率的时间趋势,并评估高血压是否与肺癌风险独立相关。方法分析2002年至2019年参加中国慢性病和危险因素监测(CCDRFS)项目的2,745,893名年龄≥18岁的成年人的数据。评估不同人口阶层肺癌患者高血压患病率的趋势。采用校正年龄、性别、吸烟、肥胖和地区的多变量logistic回归模型来估计肺癌合并高血压的校正优势比(aORs)。结果168427例肺癌患者(占总人数的6.1%)中,58.3%合并高血压。肺癌患者高血压患病率从2002年的47.2%上升到2019年的62.8%,其中农村地区(49.3% - 66.1%)和西部地区(50.4% - 66.9%)增幅较大。调整后,高血压与肺癌独立相关(aOR = 1.37; 95% CI: 1.31-1.43),在女性(aOR = 1.49)、年龄≥60岁(aOR = 1.54)、非吸烟者(aOR = 1.44)和肥胖参与者(aOR = 1.46)中观察到更强的相关性。结论高血压在中国肺癌患者中非常普遍,并可能与肺癌风险增加独立相关。这些发现表明,需要对心血管肿瘤进行综合监测和预防策略,特别是对老年人、妇女和非吸烟者等高危人群。进一步的前瞻性研究有必要探索这种关联的机制,并评估高血压控制是否可能影响肺癌负担。
{"title":"Hypertension and lung cancer in China (2002–2019): A nationwide study of temporal trends, demographic disparities, and independent risk associations","authors":"Yang Yu ,&nbsp;Chen Jiang ,&nbsp;Yan gao ,&nbsp;Dingqi Li ,&nbsp;Chongcheng Xi ,&nbsp;Quansheng Feng ,&nbsp;Rui He","doi":"10.1016/j.ijcrp.2025.200515","DOIUrl":"10.1016/j.ijcrp.2025.200515","url":null,"abstract":"<div><h3>Background</h3><div>Emerging evidence suggests a potential link between hypertension and cancer, yet the relationship between elevated blood pressure and lung cancer risk remains underexplored, particularly in large, population-based settings.</div></div><div><h3>Objective</h3><div>To investigate temporal trends in hypertension prevalence among lung cancer patients and to assess whether hypertension is independently associated with lung cancer risk in the Chinese adult population.</div></div><div><h3>Methods</h3><div>We analyzed data from 2,745,893 adults aged ≥18 years who participated in the China Chronic Disease and Risk Factor Surveillance (CCDRFS) program from 2002 to 2019. Trends in hypertension prevalence among lung cancer patients were assessed across demographic strata. Multivariable logistic regression models adjusted for age, sex, smoking, obesity, and region were used to estimate adjusted odds ratios (aORs) for lung cancer associated with hypertension.</div></div><div><h3>Results</h3><div>Among 168,427 lung cancer patients (6.1 % of total), 58.3 % had coexisting hypertension. Hypertension prevalence among lung cancer patients rose from 47.2 % in 2002 to 62.8 % in 2019, with sharper increases in rural (49.3 %–66.1 %) and western regions (50.4 %–66.9 %). After adjustment, hypertension was independently associated with lung cancer (aOR = 1.37; 95 % CI: 1.31–1.43), with stronger associations observed in females (aOR = 1.49), individuals aged ≥60 years (aOR = 1.54), non-smokers (aOR = 1.44), and obese participants (aOR = 1.46).</div></div><div><h3>Conclusions</h3><div>Hypertension is highly prevalent among lung cancer patients in China and appears to be independently associated with increased lung cancer risk. These findings suggest the need for integrated cardio-oncology surveillance and prevention strategies, particularly for high-risk subpopulations such as older adults, women, and non-smokers. Further prospective studies are warranted to explore the mechanisms underlying this association and to evaluate whether hypertension control may influence lung cancer burden.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"27 ","pages":"Article 200515"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145104931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of osteoporosis risk on in-hospital mortality in older patients with acute myocardial infarction: Insight from Tokyo CCU network database 骨质疏松风险对老年急性心肌梗死患者住院死亡率的影响:来自东京CCU网络数据库的见解
IF 2.1 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-12-01 Epub Date: 2025-11-04 DOI: 10.1016/j.ijcrp.2025.200540
Mike Saji , Shun Kohsaka , Katsumi Miyauchi , Jun Yamashita , Mikio Kishi , Hideki Miyachi , Takaaki Mase , Kohei Wakabayashi , Taku Asano , Takahide Kodama , Hajime Fujimoto , Kota Komiyama , Satoshi Kodera , Mizuki Miura , Takeshi Yamamoto , Morimasa Takayama , Toshiro Shinke

Background

Osteoporosis and cardiovascular disease often coexist in older adults, yet the prognostic impact of osteoporosis risk on outcomes of acute myocardial infarction (MI) remains unclear. This study aimed to investigate the prevalence of high osteoporosis risk and its association with in-hospital mortality among older patients with acute MI.

Methods

We analyzed 8591 consecutive patients admitted with acute MI and registered in the Tokyo CCU Network Database between 2021 and 2022. Patients were stratified into tertiles according to OST values, separately for men and women. The primary outcome was in-hospital all-cause mortality. Multivariate logistic regression, forest plots, and restricted cubic spline models were applied to assess the association between OST and the primary outcome.

Results

According to the OST criteria, 23.1 % (1503/6493) of men and 85.3 % (1791/2098) of women were classified as high risk for osteoporosis. Among those aged ≥65 years, 39.2 % (1500/3828) of men and 95.2 % (1717/1804) of women were classified as high risk. In-hospital all-cause mortality rates were 2.9 % in OST Tertile 1, 4.0 % in Tertile 2, and 10.0 % in Tertile 3 (p < 0.001). After multivariable adjustment, OST Tertile 3 remained independently associated with increased in-hospital mortality (adjusted odds ratio 2.08; 95 % CI, 1.44–3.01) compared with Tertile 1.

Conclusions

High osteoporosis risk, as estimated by the OST, was common and independently associated with increased in-hospital mortality among patients with acute MI. These findings suggest that simple screening for osteoporosis risk may help identify vulnerable older adults at higher risk of adverse outcomes following acute MI.
背景:骨质疏松症和心血管疾病在老年人中经常共存,但骨质疏松症风险对急性心肌梗死(MI)预后的影响尚不清楚。本研究旨在调查老年急性心肌梗死患者中高骨质疏松风险的患病率及其与住院死亡率的关系。方法我们分析了2021年至2022年期间在东京CCU网络数据库中登记的8591例连续入院的急性心肌梗死患者。根据OST值将患者分为男性和女性两组。主要终点是院内全因死亡率。应用多元逻辑回归、森林图和受限三次样条模型来评估OST与主要结局之间的关系。结果根据OST标准,23.1%(1503/6493)的男性和85.3%(1791/2098)的女性被归为骨质疏松高危人群。在≥65岁的人群中,39.2%(1500/3828)的男性和95.2%(1717/1804)的女性被归为高危人群。住院全因死亡率OST t1组为2.9%,t2组为4.0%,t3组为10.0% (p < 0.001)。多变量调整后,与Tertile 1相比,OST Tertile 3与住院死亡率的增加仍然独立相关(校正优势比2.08;95% CI, 1.44-3.01)。根据OST的估计,高骨质疏松风险与急性心肌梗死患者住院死亡率增加相关。这些发现表明,简单的骨质疏松风险筛查可能有助于识别急性心肌梗死后不良后果风险较高的易感老年人。
{"title":"Impact of osteoporosis risk on in-hospital mortality in older patients with acute myocardial infarction: Insight from Tokyo CCU network database","authors":"Mike Saji ,&nbsp;Shun Kohsaka ,&nbsp;Katsumi Miyauchi ,&nbsp;Jun Yamashita ,&nbsp;Mikio Kishi ,&nbsp;Hideki Miyachi ,&nbsp;Takaaki Mase ,&nbsp;Kohei Wakabayashi ,&nbsp;Taku Asano ,&nbsp;Takahide Kodama ,&nbsp;Hajime Fujimoto ,&nbsp;Kota Komiyama ,&nbsp;Satoshi Kodera ,&nbsp;Mizuki Miura ,&nbsp;Takeshi Yamamoto ,&nbsp;Morimasa Takayama ,&nbsp;Toshiro Shinke","doi":"10.1016/j.ijcrp.2025.200540","DOIUrl":"10.1016/j.ijcrp.2025.200540","url":null,"abstract":"<div><h3>Background</h3><div>Osteoporosis and cardiovascular disease often coexist in older adults, yet the prognostic impact of osteoporosis risk on outcomes of acute myocardial infarction (MI) remains unclear. This study aimed to investigate the prevalence of high osteoporosis risk and its association with in-hospital mortality among older patients with acute MI.</div></div><div><h3>Methods</h3><div>We analyzed 8591 consecutive patients admitted with acute MI and registered in the Tokyo CCU Network Database between 2021 and 2022. Patients were stratified into tertiles according to OST values, separately for men and women. The primary outcome was in-hospital all-cause mortality. Multivariate logistic regression, forest plots, and restricted cubic spline models were applied to assess the association between OST and the primary outcome.</div></div><div><h3>Results</h3><div>According to the OST criteria, 23.1 % (1503/6493) of men and 85.3 % (1791/2098) of women were classified as high risk for osteoporosis. Among those aged ≥65 years, 39.2 % (1500/3828) of men and 95.2 % (1717/1804) of women were classified as high risk. In-hospital all-cause mortality rates were 2.9 % in OST Tertile 1, 4.0 % in Tertile 2, and 10.0 % in Tertile 3 (p &lt; 0.001). After multivariable adjustment, OST Tertile 3 remained independently associated with increased in-hospital mortality (adjusted odds ratio 2.08; 95 % CI, 1.44–3.01) compared with Tertile 1.</div></div><div><h3>Conclusions</h3><div>High osteoporosis risk, as estimated by the OST, was common and independently associated with increased in-hospital mortality among patients with acute MI. These findings suggest that simple screening for osteoporosis risk may help identify vulnerable older adults at higher risk of adverse outcomes following acute MI.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"27 ","pages":"Article 200540"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145474141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Burden and etiology of heart failure in mainland China from 1990 to 2021: Results from the GBD 2021 study 1990年至2021年中国大陆心力衰竭的负担和病因:GBD 2021研究的结果
IF 2.1 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-12-01 Epub Date: 2025-08-22 DOI: 10.1016/j.ijcrp.2025.200497
Zhang Fang , Xiaofang Luo , Yuhui Zhang , Jian Zhang

Background and aims

Heart failure (HF) represents a major global public health challenge. This study aims to report the HF prevalence and disability in mainland China from 1990 to 2021, as well as the underlying etiology.

Methods

Data on HF-related prevalence and years lived with disability (YLDs) were obtained from Global Burden of Disease 2021 study for mainland China. Analyses were conducted by age and sex, with the burden rates expressed per 100,000 population. Age-period-cohort models were used to describe the trajectory of HF during 1990–2021. We analyzed the potential etiologies of HF, and performed decomposition analysis to quantify the main drivers of changes in the burden.

Results

In 2021, the prevalence and YLDs rates of HF in mainland China were 920.7 per 100,000 population (95 % uncertainty interval [UI]: 795.7–1080.8) and 90.7 per 100,000 population (95 % UI: 60.9–124.8), respectively. Both the prevalence and YLDs rates were higher in males than in females. From 1990 to 2021, the crude prevalence rate and crude YLDs rate of HF consistently increased, while the age-standardized prevalence rate and age-standardized rate of YLDs exhibited an double-peak trend. By 2021, ischemic heart disease had surpassed hypertensive heart disease as the leading cause of HF prevalence. Population aging was the largest contributor to changes in HF burden.

Conclusion

Our analysis of the GBD 2021 study indicated that the burden of HF is projected to increase substantially with an aging population. Strengthened societal efforts are urgently needed to prevent and manage HF from its causes, with particular attention to older adults.
背景和目的心力衰竭(HF)是一项重大的全球公共卫生挑战。本研究旨在报告1990 - 2021年中国大陆地区HF患病率和致残率,以及潜在病因。方法从全球疾病负担2021研究中获得中国大陆hf相关患病率和残疾生活年数(YLDs)数据。按年龄和性别进行了分析,并以每10万人的负担率表示。使用年龄-时期-队列模型来描述1990-2021年间HF的发展轨迹。我们分析了HF的潜在病因,并进行了分解分析,以量化负担变化的主要驱动因素。结果2021年中国大陆地区HF患病率为920.7 / 10万人(95%不确定区间[UI]: 795.7 ~ 1080.8),死亡率为90.7 / 10万人(95% UI: 60.9 ~ 124.8)。男性的患病率和YLDs率均高于女性。1990 - 2021年HF粗患病率和粗YLDs率呈持续上升趋势,年龄标准化患病率和年龄标准化YLDs率呈双峰趋势。到2021年,缺血性心脏病已超过高血压心脏病,成为HF患病率的主要原因。人口老龄化是HF负担变化的最大因素。我们对GBD 2021研究的分析表明,随着人口老龄化,心衰负担预计将大幅增加。迫切需要加强社会努力,从根源上预防和管理心衰,尤其要关注老年人。
{"title":"Burden and etiology of heart failure in mainland China from 1990 to 2021: Results from the GBD 2021 study","authors":"Zhang Fang ,&nbsp;Xiaofang Luo ,&nbsp;Yuhui Zhang ,&nbsp;Jian Zhang","doi":"10.1016/j.ijcrp.2025.200497","DOIUrl":"10.1016/j.ijcrp.2025.200497","url":null,"abstract":"<div><h3>Background and aims</h3><div>Heart failure (HF) represents a major global public health challenge. This study aims to report the HF prevalence and disability in mainland China from 1990 to 2021, as well as the underlying etiology.</div></div><div><h3>Methods</h3><div>Data on HF-related prevalence and years lived with disability (YLDs) were obtained from Global Burden of Disease 2021 study for mainland China. Analyses were conducted by age and sex, with the burden rates expressed per 100,000 population. Age-period-cohort models were used to describe the trajectory of HF during 1990–2021. We analyzed the potential etiologies of HF, and performed decomposition analysis to quantify the main drivers of changes in the burden.</div></div><div><h3>Results</h3><div>In 2021, the prevalence and YLDs rates of HF in mainland China were 920.7 per 100,000 population (95 % uncertainty interval [UI]: 795.7–1080.8) and 90.7 per 100,000 population (95 % UI: 60.9–124.8), respectively. Both the prevalence and YLDs rates were higher in males than in females. From 1990 to 2021, the crude prevalence rate and crude YLDs rate of HF consistently increased, while the age-standardized prevalence rate and age-standardized rate of YLDs exhibited an double-peak trend. By 2021, ischemic heart disease had surpassed hypertensive heart disease as the leading cause of HF prevalence. Population aging was the largest contributor to changes in HF burden.</div></div><div><h3>Conclusion</h3><div>Our analysis of the GBD 2021 study indicated that the burden of HF is projected to increase substantially with an aging population. Strengthened societal efforts are urgently needed to prevent and manage HF from its causes, with particular attention to older adults.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"27 ","pages":"Article 200497"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144916332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comorbidity patterns and mortality in HFpEF: A retrospective longitudinal cohort study HFpEF的共病模式和死亡率:一项回顾性纵向队列研究
IF 2.1 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-12-01 Epub Date: 2025-10-10 DOI: 10.1016/j.ijcrp.2025.200526
Mohammed Yousufuddin , Zeliang Ma , Ebrahim Barkoudah , Muhammad Waqas Tahir , Ali Yazdanyar , Rani Chikkanna , Khalid Benkhadra , Sumit Bhagra , Gregg C. Fonarow , Mohamad H. Yamani

Background

Comorbid conditions (CCs) in heart failure with preserved ejection fraction (HFpEF) are associated with poor prognosis, but the influence of their duration on mortality remains unclear. We examined how pre-admission comorbidity duration affects long-term mortality after HFpEF hospitalization.

Methods

This retrospective study included adults hospitalized for HFpEF at 17 hospitals (2010–2022) with follow-up through July 2024. Twelve individual and four system-based comorbidities present at admission were classified by duration: new (<0.5 years), early (0.5–<3 years), intermediate (3–<6 years), and long-term (>6 years). Mortality was further stratified by Get With The Guidelines–Heart Failure (GWTG) score (1, 2, ≥3) and discharge SGLT2i prescription. Cox regression and restricted cubic splines estimated risk.

Results

Among 9256 patients (mean age 77.8 years; 54.1 % female; 40.2 % rural), 64.1 % died over a median follow-up of 2.7 years. Comorbidity prevalence ranged from 6.0 % (neurological) to 73.4 % (hypertension), with durations from 0.5 years (obesity) to 5 years (diabetes). Most comorbidities increased mortality risk (HRs 1.06–1.25), highest for neurological disease, CKD, stroke, and anemia. Risk rose within 3 years of comorbidity onset, then stabilized, consistent across age, sex, and residential status. Associations persisted across GWTG strata. SGLT2i therapy attenuated mortality risk for most comorbidities, though residual risk remained for stroke, CKD, chronic lung, and neurological disease.

Conclusions

In HFpEF, comorbidities are common and associated with higher mortality, especially within the first 3 years. Prognostic effects persisted across GWTG strata, while SGLT2i therapy attenuated these risks, highlighting the importance of early detection and optimized therapy.
背景:伴射血分数(HFpEF)心力衰竭的合并症(CCs)与不良预后相关,但其持续时间对死亡率的影响尚不清楚。我们研究了入院前合并症持续时间如何影响HFpEF住院后的长期死亡率。方法本回顾性研究纳入17家医院(2010-2022年)因HFpEF住院的成年人,随访至2024年7月。入院时出现的12个个体和4个基于系统的合并症按持续时间分类:新发(0.5年)、早期(0.5 - 3年)、中期(3 - 6年)和长期(6年)。死亡率根据指南-心力衰竭(GWTG)评分(1、2、≥3)和出院SGLT2i处方进一步分层。Cox回归和受限三次样条估计风险。结果9256例患者(平均年龄77.8岁,女性占54.1%,农村占40.2%)中位随访2.7年,64.1%的患者死亡。合并症患病率从6.0%(神经系统)到73.4%(高血压),持续时间从0.5年(肥胖)到5年(糖尿病)。大多数合并症增加了死亡风险(hr 1.06-1.25),最高的是神经系统疾病、慢性肾病、中风和贫血。风险在共病发作的3年内上升,然后趋于稳定,在不同年龄、性别和居住状态下保持一致。关联在GWTG各层中持续存在。SGLT2i治疗降低了大多数合并症的死亡风险,但卒中、CKD、慢性肺和神经系统疾病的风险仍然存在。结论HFpEF的合并症很常见,且与较高的死亡率相关,尤其是在前3年内。预后影响在GWTG各层持续存在,而SGLT2i治疗降低了这些风险,强调了早期发现和优化治疗的重要性。
{"title":"Comorbidity patterns and mortality in HFpEF: A retrospective longitudinal cohort study","authors":"Mohammed Yousufuddin ,&nbsp;Zeliang Ma ,&nbsp;Ebrahim Barkoudah ,&nbsp;Muhammad Waqas Tahir ,&nbsp;Ali Yazdanyar ,&nbsp;Rani Chikkanna ,&nbsp;Khalid Benkhadra ,&nbsp;Sumit Bhagra ,&nbsp;Gregg C. Fonarow ,&nbsp;Mohamad H. Yamani","doi":"10.1016/j.ijcrp.2025.200526","DOIUrl":"10.1016/j.ijcrp.2025.200526","url":null,"abstract":"<div><h3>Background</h3><div>Comorbid conditions (CCs) in heart failure with preserved ejection fraction (HFpEF) are associated with poor prognosis, but the influence of their duration on mortality remains unclear. We examined how pre-admission comorbidity duration affects long-term mortality after HFpEF hospitalization.</div></div><div><h3>Methods</h3><div>This retrospective study included adults hospitalized for HFpEF at 17 hospitals (2010–2022) with follow-up through July 2024. Twelve individual and four system-based comorbidities present at admission were classified by duration: new (&lt;0.5 years), early (0.5–&lt;3 years), intermediate (3–&lt;6 years), and long-term (&gt;6 years). Mortality was further stratified by Get With The Guidelines–Heart Failure (GWTG) score (1, 2, ≥3) and discharge SGLT2i prescription. Cox regression and restricted cubic splines estimated risk.</div></div><div><h3>Results</h3><div>Among 9256 patients (mean age 77.8 years; 54.1 % female; 40.2 % rural), 64.1 % died over a median follow-up of 2.7 years. Comorbidity prevalence ranged from 6.0 % (neurological) to 73.4 % (hypertension), with durations from 0.5 years (obesity) to 5 years (diabetes). Most comorbidities increased mortality risk (HRs 1.06–1.25), highest for neurological disease, CKD, stroke, and anemia. Risk rose within 3 years of comorbidity onset, then stabilized, consistent across age, sex, and residential status. Associations persisted across GWTG strata. SGLT2i therapy attenuated mortality risk for most comorbidities, though residual risk remained for stroke, CKD, chronic lung, and neurological disease.</div></div><div><h3>Conclusions</h3><div>In HFpEF, comorbidities are common and associated with higher mortality, especially within the first 3 years. Prognostic effects persisted across GWTG strata, while SGLT2i therapy attenuated these risks, highlighting the importance of early detection and optimized therapy.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"27 ","pages":"Article 200526"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145332463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Addressing discrepancies in symptom and psychosocial assessments in hypertrophic cardiomyopathy 解决肥厚性心肌病症状和心理社会评估的差异
IF 2.1 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-12-01 Epub Date: 2025-08-28 DOI: 10.1016/j.ijcrp.2025.200504
Brijesh Sathian, Abdalla Fadul, Yasir Alabbas, Hanadi Al Hamad
This correspondence critiques a 2025 study by Tsenov et al. on hypertrophic cardiomyopathy, highlighting discrepancies in reported symptom burden, psychological support, employment impact, diagnostic delays, activity restrictions, and medication tolerability. Recent evidence suggests improved outcomes with novel therapies and integrated care, challenging the study's conclusions. We advocate for reconciled analyses and future longitudinal studies to enhance patient-centered hypertrophic cardiomyopathy management.
本文对2025年Tsenov等人关于肥厚性心肌病的研究进行了批评,强调了报告的症状负担、心理支持、就业影响、诊断延迟、活动限制和药物耐受性方面的差异。最近的证据表明,新疗法和综合护理可以改善结果,这对研究结论提出了挑战。我们提倡调和分析和未来的纵向研究,以加强以患者为中心的肥厚性心肌病管理。
{"title":"Addressing discrepancies in symptom and psychosocial assessments in hypertrophic cardiomyopathy","authors":"Brijesh Sathian,&nbsp;Abdalla Fadul,&nbsp;Yasir Alabbas,&nbsp;Hanadi Al Hamad","doi":"10.1016/j.ijcrp.2025.200504","DOIUrl":"10.1016/j.ijcrp.2025.200504","url":null,"abstract":"<div><div>This correspondence critiques a 2025 study by Tsenov et al. on hypertrophic cardiomyopathy, highlighting discrepancies in reported symptom burden, psychological support, employment impact, diagnostic delays, activity restrictions, and medication tolerability. Recent evidence suggests improved outcomes with novel therapies and integrated care, challenging the study's conclusions. We advocate for reconciled analyses and future longitudinal studies to enhance patient-centered hypertrophic cardiomyopathy management.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"27 ","pages":"Article 200504"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144925232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cancer as a novel risk factor for major cardiovascular adverse events in secondary prevention 癌症是二级预防中主要心血管不良事件的新危险因素
IF 2.1 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-12-01 Epub Date: 2025-08-26 DOI: 10.1016/j.ijcrp.2025.200501
Renzo Melchiori , Sara Diaz Saravia , Pablo M. Rubio , Lucas Szlaien , Romina Mouriño , Martin O'Flaherty , Manglio Rizzo , Alejandro Hita

Introduction

The inflammatory mechanisms of cancer can be associated with atherosclerosis development and progression. Although the incidence of events in secondary prevention following a first acute coronary syndrome is poorly documented.

Methods

A retrospective cohort study including patients who underwent a coronary angiography for first Acute Coronary Syndrome (ACS), and without prior history of Major Cardiovascular Events (MACE) from 2008 to 2023 was analyzed. Included patients were grouped according to the absence or presence of cancer: G1 non-oncologic, and G2 oncologic (either prior or current history). We compared the incidence rate ratio of MACE within 3 years after ACS between groups Time-to-event analysis was conducted through proportional Cox regression analysis, estimating hazard ratio, and corresponding 95 % confidence intervals (95 % CI)

Results

Of 937 patients who underwent a coronary angiography, 787 patients were included, of which 88.7 % (n = 698) presented without cancer. Over a median follow-up time of 48 months [IQR = 14–72], the incidence rate of MACE was 4.4 cases per 1000 patients/months of follow-up (n = 173 MACE events). When comparing both groups, the incidence rate ratio of MACE was 1.9 (95 % CI 1.24–2.99), significantly increased in the cancer group (P = 0.0032). Cancer was an independent predictor of MACE after adjustment for traditional cardiovascular risk factors (HR 1.84, 95 % CI 1.19–2.85; P = 0.006).

Conclusions

Patients with cancer represent a novel independent risk factor for MACE, even following secondary preventive therapies. These results highlight future endpoints for cardiovascular prevention and further public health interventions in this population.
癌症的炎症机制可能与动脉粥样硬化的发展和进展有关。尽管首次急性冠状动脉综合征后二级预防事件的发生率文献很少。方法回顾性分析2008 - 2023年首次急性冠脉综合征(ACS)行冠状动脉造影且无重大心血管事件(MACE)病史的患者。纳入的患者根据有无癌症分组:G1非肿瘤性和G2肿瘤性(既往或当前病史)。我们比较各组间ACS后3年内MACE的发生率比,通过比例Cox回归分析进行时间-事件分析,估计风险比和相应的95%可信区间(95% CI)。结果在937例接受冠状动脉造影的患者中,纳入787例患者,其中89.7% (n = 698)未出现癌症。中位随访时间为48个月[IQR = 14-72], MACE发生率为每1000例患者/月4.4例(n = 173例MACE事件)。两组比较,MACE的发生率比为1.9 (95% CI 1.24-2.99),肿瘤组明显升高(P = 0.0032)。校正传统心血管危险因素后,癌症是MACE的独立预测因子(HR 1.84, 95% CI 1.19-2.85; P = 0.006)。结论癌症患者是MACE的一个新的独立危险因素,即使在二级预防治疗后也是如此。这些结果强调了心血管预防和进一步公共卫生干预在这一人群中的未来终点。
{"title":"Cancer as a novel risk factor for major cardiovascular adverse events in secondary prevention","authors":"Renzo Melchiori ,&nbsp;Sara Diaz Saravia ,&nbsp;Pablo M. Rubio ,&nbsp;Lucas Szlaien ,&nbsp;Romina Mouriño ,&nbsp;Martin O'Flaherty ,&nbsp;Manglio Rizzo ,&nbsp;Alejandro Hita","doi":"10.1016/j.ijcrp.2025.200501","DOIUrl":"10.1016/j.ijcrp.2025.200501","url":null,"abstract":"<div><h3>Introduction</h3><div>The inflammatory mechanisms of cancer can be associated with atherosclerosis development and progression. Although the incidence of events in secondary prevention following a first acute coronary syndrome is poorly documented.</div></div><div><h3>Methods</h3><div>A retrospective cohort study including patients who underwent a coronary angiography for first Acute Coronary Syndrome (ACS), and without prior history of Major Cardiovascular Events (MACE) from 2008 to 2023 was analyzed. Included patients were grouped according to the absence or presence of cancer: G1 non-oncologic, and G2 oncologic (either prior or current history). We compared the incidence rate ratio of MACE within 3 years after ACS between groups Time-to-event analysis was conducted through proportional Cox regression analysis, estimating hazard ratio, and corresponding 95 % confidence intervals (95 % CI)</div></div><div><h3>Results</h3><div>Of 937 patients who underwent a coronary angiography, 787 patients were included, of which 88.7 % (n = 698) presented without cancer. Over a median follow-up time of 48 months [IQR = 14–72], the incidence rate of MACE was 4.4 cases per 1000 patients/months of follow-up (n = 173 MACE events). When comparing both groups, the incidence rate ratio of MACE was 1.9 (95 % CI 1.24–2.99), significantly increased in the cancer group (P = 0.0032). Cancer was an independent predictor of MACE after adjustment for traditional cardiovascular risk factors (HR 1.84, 95 % CI 1.19–2.85; P = 0.006).</div></div><div><h3>Conclusions</h3><div>Patients with cancer represent a novel independent risk factor for MACE, even following secondary preventive therapies. These results highlight future endpoints for cardiovascular prevention and further public health interventions in this population.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"27 ","pages":"Article 200501"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144988271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pheochromocytoma and heart rate variability: a systematic review and meta-analysis 嗜铬细胞瘤和心率变异性:一项系统回顾和荟萃分析
IF 2.1 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-12-01 Epub Date: 2025-08-19 DOI: 10.1016/j.ijcrp.2025.200493
Frédéric Dutheil , Naira El Gritli , Valentin Magnon , Marek Zak , Reza Bagheri , Julien Steven Baker , Ukadike Chris Ugbolue , Jean-Baptiste Bouillon-Minois , Igor Tauveron , Luc Vialatte

Introduction

Pheochromocytoma is a catecholamine-producing tumor, that may alter cardiovascular activity. Conveniently, sympathovagal activity can be measured non-intrusively and pain-free through heart rate variability (HRV).

Objective

To conduct a systematic review and meta-analysis on the impact of pheochromocytoma on HRV parameters.

Methods

PubMed, Cochrane, Embase and Google Scholar were searched until October 10, 2024 for articles reporting HRV parameters in pheochromocytoma patients. Random-effects meta-analysis were conducted on each HRV parameters stratified on pheochromocytoma patients and controls and then comparing these two groups: RR intervals (or Normal-to-Normal intervals-NN), SDNN (Standard Deviation of RR intervals), RMSSD (square root of the mean difference of successive RR intervals), pNN50 (percentage of RR intervals with >50 ms of variation), LF (low-frequency) and HF (high-frequency), and LF/HF.

Results

We included six studies for a total of 178 patients: 94 with pheochromocytoma and 84 controls. Compared to controls, pheochromocytoma patients had higher vagal activity with higher HF (ES = 0.50, 95CI 0.04 to 0.96) and rMSSD (1.22, 0.09 to 2.35), and a tendency for higher pNN50 (1.14, −0.14 to 2.41). The sympathovagal balance tended to be higher in pheochromocytoma patients compared to controls with a tendency for a decreased LF/HF (−0.97, −2.03 to 0.09). Pheochromocytoma patients also tended to have lower RR-intervals than controls (−0.39, −0.86 to 0.07). Sympathetic activity (LF and SDNN) did not differ between pheochromocytoma and controls.

Conclusion

Paradoxically, pheochromocytoma patients have higher HRV. The sympathovagal balance may be explained by a desensitization of beta-adrenergic receptors consecutive to chronic high levels of catecholamine.
嗜铬细胞瘤是一种产生儿茶酚胺的肿瘤,可改变心血管活动。方便的是,交感迷走神经活动可以通过心率变异性(HRV)无创无痛地测量。目的对嗜铬细胞瘤对HRV参数的影响进行系统评价和meta分析。方法检索spubmed、Cochrane、Embase和谷歌Scholar,检索到2024年10月10日报道嗜铬细胞瘤患者HRV参数的文章。对嗜铬细胞瘤患者和对照组分层的HRV参数进行随机效应荟萃分析,比较两组的HRV参数:RR区间(或称正态至正态区间- nn)、SDNN (RR区间标准差)、RMSSD(连续RR区间均值差的平方根)、pNN50(变异率为>;50 ms的RR区间百分比)、LF(低频)和HF(高频)、LF/HF。结果我们纳入了6项研究,共178例患者:94例嗜铬细胞瘤患者和84例对照组。与对照组相比,嗜铬细胞瘤患者迷走神经活动较高,HF (ES = 0.50, 95CI 0.04 ~ 0.96)和rMSSD(1.22, 0.09 ~ 2.35)较高,pNN50倾向较高(1.14,- 0.14 ~ 2.41)。与对照组相比,嗜铬细胞瘤患者交感迷走神经平衡倾向于更高,且有降低LF/HF的趋势(- 0.97,- 2.03 - 0.09)。嗜铬细胞瘤患者的rr间隔也往往低于对照组(- 0.39,- 0.86至0.07)。交感神经活动(LF和SDNN)在嗜铬细胞瘤和对照组之间没有差异。结论嗜铬细胞瘤患者有较高的HRV。交感迷走神经平衡可以解释为β -肾上腺素能受体的脱敏,连续慢性高水平的儿茶酚胺。
{"title":"Pheochromocytoma and heart rate variability: a systematic review and meta-analysis","authors":"Frédéric Dutheil ,&nbsp;Naira El Gritli ,&nbsp;Valentin Magnon ,&nbsp;Marek Zak ,&nbsp;Reza Bagheri ,&nbsp;Julien Steven Baker ,&nbsp;Ukadike Chris Ugbolue ,&nbsp;Jean-Baptiste Bouillon-Minois ,&nbsp;Igor Tauveron ,&nbsp;Luc Vialatte","doi":"10.1016/j.ijcrp.2025.200493","DOIUrl":"10.1016/j.ijcrp.2025.200493","url":null,"abstract":"<div><h3>Introduction</h3><div>Pheochromocytoma is a catecholamine-producing tumor, that may alter cardiovascular activity. Conveniently, sympathovagal activity can be measured non-intrusively and pain-free through heart rate variability (HRV).</div></div><div><h3>Objective</h3><div>To conduct a systematic review and meta-analysis on the impact of pheochromocytoma on HRV parameters.</div></div><div><h3>Methods</h3><div>PubMed, Cochrane, Embase and Google Scholar were searched until October 10, 2024 for articles reporting HRV parameters in pheochromocytoma patients. Random-effects meta-analysis were conducted on each HRV parameters stratified on pheochromocytoma patients and controls and then comparing these two groups: RR intervals (or Normal-to-Normal intervals-NN), SDNN (Standard Deviation of RR intervals), RMSSD (square root of the mean difference of successive RR intervals), pNN50 (percentage of RR intervals with &gt;50 ms of variation), LF (low-frequency) and HF (high-frequency), and LF/HF.</div></div><div><h3>Results</h3><div>We included six studies for a total of 178 patients: 94 with pheochromocytoma and 84 controls. Compared to controls, pheochromocytoma patients had higher vagal activity with higher HF (ES = 0.50, 95CI 0.04 to 0.96) and rMSSD (1.22, 0.09 to 2.35), and a tendency for higher pNN50 (1.14, −0.14 to 2.41). The sympathovagal balance tended to be higher in pheochromocytoma patients compared to controls with a tendency for a decreased LF/HF (−0.97, −2.03 to 0.09). Pheochromocytoma patients also tended to have lower RR-intervals than controls (−0.39, −0.86 to 0.07). Sympathetic activity (LF and SDNN) did not differ between pheochromocytoma and controls.</div></div><div><h3>Conclusion</h3><div>Paradoxically, pheochromocytoma patients have higher HRV. The sympathovagal balance may be explained by a desensitization of beta-adrenergic receptors consecutive to chronic high levels of catecholamine.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"27 ","pages":"Article 200493"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144864260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diurnal temperature range and hospital admission due to cardiovascular diseases: A systematic review and meta-analysis study 昼夜温度范围与心血管疾病住院:一项系统回顾和荟萃分析研究
IF 2.1 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-12-01 Epub Date: 2025-08-15 DOI: 10.1016/j.ijcrp.2025.200487
Hamidreza Aghababaeian , Mostafa Hadei , Mahsa Sepasian , Masoumeh Gharaee , Ladan Araghi Ahvazi , Rahim Sharafkhani , Mohammad Zarei
This study investigated the impact of the diurnal temperature range (DTR) on hospitalizations related to cardiovascular disease (CVD). Following the PRISMA protocol, a systematic review and meta-analysis searched various databases for English studies using keywords related to DTR and CVD up to June 1, 2023. A random-effects meta-analysis model was utilized to aggregate previous estimates of DTR effects on CVD admissions. The findings revealed that a 1 °C increase in DTR is associated with a 1.5 % increase in all CVD hospitalizations (95 % CI: 0.2 %, 3 %). Additionally, for each 1 °C increase in DTR, admissions due to acute myocardial infarction (AMI) and heart failure increased by relative risks (RR) of 1.02 (95 % CI: 1.01, 1.03) and 1.04 (95 % CI: 1.03, 1.04), respectively. Our analysis showed that a 1 °C increase in DTR was associated with a 0.9 % increase in all CVD hospital admissions among those aged ≥65 years (95 % CI: 0.3 %, 1.6 %). The overall estimates indicated that DTR (per 1 °C increment) was associated with a 0.6 % (95 % CI: 0.2 %, 1.1 %) increase in females and a 1.7 % (95 % CI: 1.3 %, 2.2 %) increase in males. It was statistically significant for elderly individuals, corresponding to a 4.5 % increase in stroke risk (RR: 1.045 [95 % CI: 1.01, 1.07]). Overall, this study emphasizes that daily fluctuations in DTR increase the hospitalization risk in cardiovascular patients, highlighting the need to consider the effects of DTR on cardiovascular health, especially among vulnerable age and sex groups.
本研究探讨了昼夜温度范围(DTR)对心血管疾病(CVD)相关住院的影响。根据PRISMA协议,系统回顾和荟萃分析检索了截至2023年6月1日的英语研究数据库,使用与DTR和CVD相关的关键词。随机效应荟萃分析模型用于汇总先前对DTR对心血管疾病入院的影响的估计。研究结果显示,DTR升高1°C与所有心血管疾病住院率增加1.5%相关(95% CI: 0.2%, 3%)。此外,DTR每增加1°C,因急性心肌梗死(AMI)和心力衰竭入院的相对风险(RR)分别增加1.02 (95% CI: 1.01, 1.03)和1.04 (95% CI: 1.03, 1.04)。我们的分析显示,在年龄≥65岁的患者中,DTR升高1°C与所有心血管疾病住院率增加0.9%相关(95% CI: 0.3%, 1.6%)。总体估计表明,DTR(每增加1°C)与女性增加0.6% (95% CI: 0.2%, 1.1%)和男性增加1.7% (95% CI: 1.3%, 2.2%)相关。老年人中风风险增加4.5%,差异有统计学意义(RR: 1.045 [95% CI: 1.01, 1.07])。总体而言,本研究强调DTR的日常波动增加了心血管患者的住院风险,强调需要考虑DTR对心血管健康的影响,特别是在脆弱年龄和性别群体中。
{"title":"Diurnal temperature range and hospital admission due to cardiovascular diseases: A systematic review and meta-analysis study","authors":"Hamidreza Aghababaeian ,&nbsp;Mostafa Hadei ,&nbsp;Mahsa Sepasian ,&nbsp;Masoumeh Gharaee ,&nbsp;Ladan Araghi Ahvazi ,&nbsp;Rahim Sharafkhani ,&nbsp;Mohammad Zarei","doi":"10.1016/j.ijcrp.2025.200487","DOIUrl":"10.1016/j.ijcrp.2025.200487","url":null,"abstract":"<div><div>This study investigated the impact of the diurnal temperature range (DTR) on hospitalizations related to cardiovascular disease (CVD). Following the PRISMA protocol, a systematic review and meta-analysis searched various databases for English studies using keywords related to DTR and CVD up to June 1, 2023. A random-effects meta-analysis model was utilized to aggregate previous estimates of DTR effects on CVD admissions. The findings revealed that a 1 °C increase in DTR is associated with a 1.5 % increase in all CVD hospitalizations (95 % CI: 0.2 %, 3 %). Additionally, for each 1 °C increase in DTR, admissions due to acute myocardial infarction (AMI) and heart failure increased by relative risks (RR) of 1.02 (95 % CI: 1.01, 1.03) and 1.04 (95 % CI: 1.03, 1.04), respectively. Our analysis showed that a 1 °C increase in DTR was associated with a 0.9 % increase in all CVD hospital admissions among those aged ≥65 years (95 % CI: 0.3 %, 1.6 %). The overall estimates indicated that DTR (per 1 °C increment) was associated with a 0.6 % (95 % CI: 0.2 %, 1.1 %) increase in females and a 1.7 % (95 % CI: 1.3 %, 2.2 %) increase in males. It was statistically significant for elderly individuals, corresponding to a 4.5 % increase in stroke risk (RR: 1.045 [95 % CI: 1.01, 1.07]). Overall, this study emphasizes that daily fluctuations in DTR increase the hospitalization risk in cardiovascular patients, highlighting the need to consider the effects of DTR on cardiovascular health, especially among vulnerable age and sex groups.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"27 ","pages":"Article 200487"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144878403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phenotype-specific associations of circulating adipokine levels with carotid atherosclerosis: a systematic review and meta-analysis 循环脂肪因子水平与颈动脉粥样硬化的表型特异性关联:系统回顾和荟萃分析
IF 2.1 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-12-01 Epub Date: 2025-11-12 DOI: 10.1016/j.ijcrp.2025.200543
Shuo Yang , Hong Shen , Yukun You , Zhenyue Fu , Shuaijie Guo , Yifan Zhang , Qincheng Liu , Ying Yang , Ye Li , Ji Qin , Ping Liu

Background

Atherosclerosis (AS) is driven by inflammatory and metabolic dysregulation. Carotid atherosclerosis (CA), assessable by ultrasonographic carotid intima–media thickness (cIMT) and plaque, provides a noninvasive window into AS. Adipose tissue–derived adipokines are involved in AS.

Aim

We conducted a phenotype-specific systematic review and meta-analysis of observational studies to quantify associations between circulating adipokines and CA.

Methods

Following a preregistered protocol, PubMed, Embase, and Web of Science were searched. Adults with ultrasound-defined CA (increased cIMT and/or carotid plaque) and controls were included. Mean and standard deviation (SD) of circulating adipokines were extracted and converted to standardized mean difference (SMD) for pooled analysis.

Results

Nineteen studies (n = 5860; Asia/Europe/Americas; 8 cross-sectional, 8 case-control, 3 cohort) were included for quantitative analysis. In the increased cIMT phenotype, adiponectin was lower in CA [SMD = −0.72 (−1.00, −0.44), P < 0.05], whereas in the plaque phenotype it was higher [SMD = 0.29 (0.11, 0.47), P < 0.05]. Leptin was higher in CA, reaching significance in the plaque phenotype [SMD = 0.70 (0.13, 1.28), P = 0.02]. Omentin was consistently lower in CA across phenotypes [SMD = −1.43 (−2.20, −0.66), P < 0.001]. Sensitivity analysis supported robustness for adiponectin (stronger effects after excluding healthy cohorts), and publication-bias assessment was feasible only for adiponectin and were negative.

Conclusions

This study indicated that circulating adipokine levels can serve as phenotype-specific biomarkers in CA.
动脉粥样硬化(AS)是由炎症和代谢失调驱动的。颈动脉粥样硬化(CA),通过超声颈动脉内膜-中膜厚度(cIMT)和斑块来评估,为观察AS提供了一个无创窗口。脂肪组织来源的脂肪因子参与AS。我们对观察性研究进行了表型特异性的系统回顾和荟萃分析,以量化循环脂肪因子与ca之间的关系。方法按照预先注册的方案,检索PubMed, Embase和Web of Science。包括超声诊断的CA (cIMT增加和/或颈动脉斑块)和对照组的成年人。提取循环脂肪因子的均值和标准差(SD)并转换为标准化平均差(SMD)进行合并分析。结果纳入19项研究(n = 5860,亚洲/欧洲/美洲,横断面8项,病例对照8项,队列3项)进行定量分析。在cIMT表型增加的情况下,CA的脂联素水平较低[SMD = - 0.72 (- 1.00, - 0.44), P < 0.05],而斑块表型的脂联素水平较高[SMD = 0.29 (0.11, 0.47), P < 0.05]。瘦素在CA中升高,对斑块表型有显著影响[SMD = 0.70 (0.13, 1.28), P = 0.02]。在不同表型的CA中,Omentin均较低[SMD = - 1.43 (- 2.20, - 0.66), P < 0.001]。敏感性分析支持脂联素的稳健性(排除健康队列后效果更强),发表偏倚评估仅适用于脂联素,结果为阴性。结论本研究表明,循环脂肪因子水平可作为CA的表型特异性生物标志物。
{"title":"Phenotype-specific associations of circulating adipokine levels with carotid atherosclerosis: a systematic review and meta-analysis","authors":"Shuo Yang ,&nbsp;Hong Shen ,&nbsp;Yukun You ,&nbsp;Zhenyue Fu ,&nbsp;Shuaijie Guo ,&nbsp;Yifan Zhang ,&nbsp;Qincheng Liu ,&nbsp;Ying Yang ,&nbsp;Ye Li ,&nbsp;Ji Qin ,&nbsp;Ping Liu","doi":"10.1016/j.ijcrp.2025.200543","DOIUrl":"10.1016/j.ijcrp.2025.200543","url":null,"abstract":"<div><h3>Background</h3><div>Atherosclerosis (AS) is driven by inflammatory and metabolic dysregulation. Carotid atherosclerosis (CA), assessable by ultrasonographic carotid intima–media thickness (cIMT) and plaque, provides a noninvasive window into AS. Adipose tissue–derived adipokines are involved in AS.</div></div><div><h3>Aim</h3><div>We conducted a phenotype-specific systematic review and meta-analysis of observational studies to quantify associations between circulating adipokines and CA.</div></div><div><h3>Methods</h3><div>Following a preregistered protocol, PubMed, Embase, and Web of Science were searched. Adults with ultrasound-defined CA (increased cIMT and/or carotid plaque) and controls were included. Mean and standard deviation (SD) of circulating adipokines were extracted and converted to standardized mean difference (SMD) for pooled analysis.</div></div><div><h3>Results</h3><div>Nineteen studies (n = 5860; Asia/Europe/Americas; 8 cross-sectional, 8 case-control, 3 cohort) were included for quantitative analysis. In the increased cIMT phenotype, adiponectin was lower in CA [SMD = −0.72 (−1.00, −0.44), <em>P</em> &lt; 0.05], whereas in the plaque phenotype it was higher [SMD = 0.29 (0.11, 0.47), <em>P</em> &lt; 0.05]. Leptin was higher in CA, reaching significance in the plaque phenotype [SMD = 0.70 (0.13, 1.28), P = 0.02]. Omentin was consistently lower in CA across phenotypes [SMD = −1.43 (−2.20, −0.66), P &lt; 0.001]. Sensitivity analysis supported robustness for adiponectin (stronger effects after excluding healthy cohorts), and publication-bias assessment was feasible only for adiponectin and were negative.</div></div><div><h3>Conclusions</h3><div>This study indicated that circulating adipokine levels can serve as phenotype-specific biomarkers in CA.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"27 ","pages":"Article 200543"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145525652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiac rehabilitation for outpatients aged over 80 years with cardiovascular diseases 80岁以上心血管疾病门诊患者心脏康复
IF 2.1 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2025-12-01 Epub Date: 2025-09-17 DOI: 10.1016/j.ijcrp.2025.200516
Ryoko Someya , Yasushi Matsuzawa , Yoshitaka Shimizu , Hidefumi Nakahashi , Masaaki Konishi , Eiichi Akiyama , Yohei Hanajima , Hisaya Kondo , Tomohiro Yoshii , Ryosuke Sato , Kazuko Hayashi , Kozo Okada , Teruyasu Sugano , Kiyoshi Hibi

Background

Japan had the highest proportion of the elderly in the world, with one in 10 individuals aged ≥80 years. Consequently, the number of patients with cardiovascular diseases is increasing. Older patients often have comorbidities such as frailty, sarcopenia, and cognitive decline that leads to a decreased quality of life (QOL). We analyzed the effects of outpatient cardiac rehabilitation (OCR) in elderly patients with cardiovascular disease.

Methods

The comprehensive OCR had been provided by a multidisciplinary team. We analyzed data from 49 patients with cardiovascular diseases, aged ≥80 years, who received cardiopulmonary exercise (CPX) tests based OCR. Frailty, physical function, QOL, exercise tolerance, and vascular endothelial function were assessed before and after OCR.

Results

All 49 patients had completed the OCR program. The mean patients’ age was 84.1 ± 3.6 years and 32.7 % were male. The proportion of frailty and pre-frailty participants significantly decreased from 92 % to 67 % following OCR. The QOL (KCCQ: 76.8 ± 18.4 vs. 81.4 ± 20.4; P = 0.0196), exercise tolerance (peak VO2: 14.1 ± 4.0 vs. 15.4 ± 3.9 mL/min/kg; P = 0.0017), and vascular endothelial function (Ln-RHI: 0.48 ± 0.39 vs. 0.57 ± 0.3; P = 0.027) significantly improved after OCR.

Conclusions

The comprehensive OCR with CPX-based exercise therapy and the multidisciplinary approach significantly improved frailty, the QOL, physical function, exercise tolerance, and vascular endothelial function in patients with cardiovascular diseases aged ≥80 years.
日本是世界上老年人比例最高的国家,每10个人中就有1人的年龄≥80岁。因此,心血管疾病患者的数量正在增加。老年患者通常有合并症,如虚弱、肌肉减少症和认知能力下降,导致生活质量下降(QOL)。我们分析了门诊心脏康复(OCR)在老年心血管疾病患者中的效果。方法由多学科团队提供全面的OCR。我们分析了49例年龄≥80岁的心血管疾病患者的数据,这些患者接受了基于OCR的心肺运动(CPX)试验。在OCR前后评估虚弱、身体功能、生活质量、运动耐量和血管内皮功能。结果49例患者均完成了OCR计划。患者平均年龄84.1±3.6岁,男性占32.7%。在OCR之后,虚弱和虚弱前参与者的比例从92%显著下降到67%。QOL (KCCQ: 76.8±18.4 vs. 81.4±20.4,P = 0.0196)、运动耐量(峰值VO2: 14.1±4.0 vs. 15.4±3.9 mL/min/kg, P = 0.0017)和血管内皮功能(Ln-RHI: 0.48±0.39 vs. 0.57±0.3,P = 0.027)均显著改善。结论综合OCR结合cpx为基础的运动疗法和多学科联合治疗可显著改善≥80岁心血管疾病患者的虚弱、生活质量、身体功能、运动耐量和血管内皮功能。
{"title":"Cardiac rehabilitation for outpatients aged over 80 years with cardiovascular diseases","authors":"Ryoko Someya ,&nbsp;Yasushi Matsuzawa ,&nbsp;Yoshitaka Shimizu ,&nbsp;Hidefumi Nakahashi ,&nbsp;Masaaki Konishi ,&nbsp;Eiichi Akiyama ,&nbsp;Yohei Hanajima ,&nbsp;Hisaya Kondo ,&nbsp;Tomohiro Yoshii ,&nbsp;Ryosuke Sato ,&nbsp;Kazuko Hayashi ,&nbsp;Kozo Okada ,&nbsp;Teruyasu Sugano ,&nbsp;Kiyoshi Hibi","doi":"10.1016/j.ijcrp.2025.200516","DOIUrl":"10.1016/j.ijcrp.2025.200516","url":null,"abstract":"<div><h3>Background</h3><div>Japan had the highest proportion of the elderly in the world, with one in 10 individuals aged ≥80 years. Consequently, the number of patients with cardiovascular diseases is increasing. Older patients often have comorbidities such as frailty, sarcopenia, and cognitive decline that leads to a decreased quality of life (QOL). We analyzed the effects of outpatient cardiac rehabilitation (OCR) in elderly patients with cardiovascular disease.</div></div><div><h3>Methods</h3><div>The comprehensive OCR had been provided by a multidisciplinary team. We analyzed data from 49 patients with cardiovascular diseases, aged ≥80 years, who received cardiopulmonary exercise (CPX) tests based OCR. Frailty, physical function, QOL, exercise tolerance, and vascular endothelial function were assessed before and after OCR.</div></div><div><h3>Results</h3><div>All 49 patients had completed the OCR program. The mean patients’ age was 84.1 ± 3.6 years and 32.7 % were male. The proportion of frailty and pre-frailty participants significantly decreased from 92 % to 67 % following OCR. The QOL (KCCQ: 76.8 ± 18.4 vs. 81.4 ± 20.4; P = 0.0196), exercise tolerance (peak VO<sub>2</sub>: 14.1 ± 4.0 vs. 15.4 ± 3.9 mL/min/kg; P = 0.0017), and vascular endothelial function (Ln-RHI: 0.48 ± 0.39 vs. 0.57 ± 0.3; P = 0.027) significantly improved after OCR.</div></div><div><h3>Conclusions</h3><div>The comprehensive OCR with CPX-based exercise therapy and the multidisciplinary approach significantly improved frailty, the QOL, physical function, exercise tolerance, and vascular endothelial function in patients with cardiovascular diseases aged ≥80 years.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"27 ","pages":"Article 200516"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145332464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
International Journal of Cardiology Cardiovascular Risk and Prevention
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1